Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Trading Statement

5 May 2009 07:00

RNS Number : 5915R
ViaLogy PLC
05 May 2009
 



VIALOGY PLC ("VIALOGY" OR "THE COMPANY")

Accuracy of latest oil well predictions independently confirmed

LondonMay 5, 2009Vialogy (LSE:VIY) Following the announcement on 23 April 2009 that a further oil discovery had been made on the Galba Field, Texas ("Mary Ridgeway #1"), ViaLogy is pleased to announce that it has now received detailed analysis confirming the predictions made using its QuantumRD technology on the oil find The successful well was drilled by the leaseholders, Atascosa Exploration LLC of San Antonio.

Using industry standard core analysis practices, Atascosa has received independent confirmation that the well will produce 170,000 barrels of crude oil (i.e. 35% primary recovery based on an overall actual volume of 486,000 barrels).  Atascosa plans extractions of 50% of the recoverable reserves in first three years.  ViaLogy's QuantumRD predictions of hydrocarbon pay zones at depth of 3050 feet with average porosity of 30%, and the oil reservoir's boundaries all proved correct.  With a 10% direct working Interest, ViaLogy expects to receive revenues of approximately $650,000, assuming 35% recovery, over the life of the well (assuming an average per barrel price of $50) to be paid monthly and to begin in Q2 2009.

Atascosa's Senior Geologist, Wilford Stapp commented, "I am very impressed by ViaLogy's ability to combine geological assessment with subsurface seismic interpretation to locate hydrocarbon high saturation zones in consolidated sands.  We have concluded that Mary Ridgeway #1 is a new isolated reservoir in the Bartosh formation with multiple pay zones. ViaLogy's optimized drill location has ensured that this new well will not compete with other producing wells, enhancing our total recovery from the field." Mr. Stapp has Emeritus standing with both the American Association of Petroleum Geologists and Society of Petroleum Engineers; he founded the Publication of the South Texas Geological Society, and was a Fellow of Geological Society of London.  He has been an expert practicing geologist for over 50 years working with majors and independents.  Besides Texas, Mr Stapp has worked in AsiaAustraliaDominican RepublicEnglandFranceMoroccoNamibia, and the Persian Gulf.

ViaLogy has also agreed terms with Atascosa for the drilling of a third well on the Galba Field and discussions are under way for the application of QuantumRD at a number of other Atascosa lease sites.  In addition, Vialogy expects to be working with other customers on additional oil discovery projects in the coming weeks.

Vialogy CEO, Robert Dean, commented, "The accuracy of ViaLogy's QuantumRD analysis and predictions on these first successful wells is impressive.  The technology is widely applicable, and the Company intends to demonstrate its capabilities with an increasing variety of hydrocarbon geological formations and an expanded customer set." 

For further information please contact:

ViaLogy

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807)

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 (mobile: 07860 842756) 

Atascosa Exploration LLC

John D. Mullins, CEO (+1 210-402-3656)

Nominated Advisor to ViaLogy PLC (Seymour Pierce)

Mark Percy +44 (0) 20-7107-8000 

Brokers to ViaLogy PLC (St. Helen's Capital)

Ruari McGirr / Sebastian Wykeham +44 (0) 207 628 5582  

About ViaLogy: Network Centric Signal Processing

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. ViaLogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.ViaLogy.com

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied. 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DRLUUUCAAUPBGUG
Date   Source Headline
1st Apr 201912:12 pmRNSHolding(s) in Company
25th Mar 20197:00 amRNSYourgene raises IONA® test awareness in Egypt
26th Feb 20193:21 pmRNSHolding(s) in Company
22nd Feb 201910:00 amEQSHardman & Co Research: Yourgene Health (YGEN): EBITDA-positive in fiscal 2020
22nd Feb 20198:05 amRNSHolding(s) in Company
19th Feb 20192:21 pmRNSHolding(s) in Company
19th Feb 20197:15 amEQSHardman & Co Research: Yourgene Health (YGEN): Transformed and de-risked
18th Feb 201910:59 amRNSIssue of Equity
18th Feb 20197:00 amRNSMajor Capital & Commercial Restructuring
8th Jan 20197:00 amRNSYourgene launches Sage 32 plex
3rd Dec 20187:00 amRNSHalf-year Results
7th Nov 20187:00 amRNSChange of Name to Yourgene Health plc
5th Nov 201811:24 amRNSShare Transfer
2nd Nov 20187:00 amRNSDirectorate Change
25th Oct 20183:30 pmRNSResult of AGM
25th Oct 20187:00 amRNSHolding(s) in Company
25th Oct 20187:00 amRNSAGM Statement
22nd Oct 20187:00 amRNSFurther re: Fundraise
12th Oct 20181:15 pmRNSAvailability of Research Commentary
12th Oct 20187:00 amRNSTrading Update and Notice of Results
5th Oct 20187:00 amRNSDirector's dealing and share option issue
4th Oct 20187:00 amRNS$1 million collaboration agreement
3rd Oct 20187:00 amRNSDirectorate change
2nd Oct 20187:00 amRNSNotice of AGM
1st Oct 201812:20 pmRNSResult of Fundraise
28th Sep 20185:41 pmRNSProposed fundraise to raise approximately £2.5m
28th Sep 20185:40 pmRNSFull year results and half-year trading update
25th Sep 201811:31 amRNSHolding(s) in Company
21st Sep 20184:10 pmRNSHolding(s) in Company
21st Sep 20187:00 amRNSHolding(s) in Company
20th Sep 20189:30 amRNSSenior Appointment & Anticipated Director Change
19th Sep 201811:05 amRNSSecond Price Monitoring Extn
19th Sep 201811:00 amRNSPrice Monitoring Extension
19th Sep 20187:00 amRNSLegal Settlement & Licence Agreement with Illumina
11th Sep 20187:00 amRNSHolding(s) in Company
7th Aug 201810:57 amRNSHolding(s) in Company
12th Jul 20187:00 amRNSShare option awards
4th Jul 20187:00 amRNSBoard Changes
26th Jun 20181:31 pmRNSCollaboration with Abnova
13th Jun 20187:00 amRNSOutstanding NIPS Solution Provider Award Win
11th Jun 20187:00 amRNSDNA sequencing technology development agreement
7th Jun 20183:44 pmRNSHolding(s) in Company
5th Jun 20187:00 amRNSPremaitha signs partnership agreement in India
4th Jun 201811:05 amRNSHolding(s) in Company
24th May 20187:00 amRNSHolding(s) in Company
18th May 20184:38 pmRNSHolding(s) in Company
18th May 201812:06 pmRNSHolding(s) in Company
18th May 201812:05 pmRNSHolding(s) in Company
18th May 20189:40 amRNSHoldings in Company
15th May 20187:00 amRNSPremaitha expands footprint with new laboratories

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.